Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom eye drops (tafluprost 0.0015%/timolol 0.5%)

Next Previous
X
Search
Trial Profile

A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom eye drops (tafluprost 0.0015%/timolol 0.5%)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafluprost/timolol (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Therapeutic Use
  • Sponsors Santen Oy

    • Most Recent Events

    • 20 Sep 2016 This trial was completed in Finland (end date: 2016-05-25), according to European Clinical trials Database.
    • 30 Jun 2016 This trial is completed in Germany ( end date: 25 May 2016).
    • 25 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top